Table 1.
Characteristics of the cohort and outcomes
| 76 patients | |
|---|---|
| Patient ‘s characteristics | |
| Comorbidities, n (%) | |
| Obesitya | 29 (38%) |
| Hypertension | 32 (42.1%) |
| Diabetes | 28 (36.8%) |
| Coronary artery disease | 9 (11.8%) |
| Dyslipidemia | 16 (21.1%) |
| Smoking | 15 (19.7%) |
| Immunosuppression | 5 (6.6%) |
| Chronic lung disease | 9 (11.8%) |
| Chronic kidney disease | 4 (5.3%) |
| Number of comorbidities | 0 (0–1) |
| Type of ECMO support, n (%) | |
| Veno-venous | 75 (98.7%) |
| Arteriovenous | 1 (1.3%) |
| Cardiac arrest before ECMO, n (%) | 4 (5.3%) |
| Outcome | |
| ECMO weaning, n (%) | 45 (59.2%) |
| ECMO second run, n (%) | 5 (6.6%) |
| ECMO-free days at D60 | 14 (0–36.5) |
| MV duration | 41 (27.5–54.5) |
| Mortality, n (%) | |
| Day 28 | 6 (7.9%) |
| Day 60 | 29 (38.2%) |
| Day 90 | 37 (48.7%) |
| Length of stay in ICU, (days) | 47.5 (33–65) |
| Length of stay in hospital, (days) | 50 (38–80) |
| Complications during ICU stay, n (%) | |
| Invasive aspergillosis | 4 (5.3%) |
| Viral reactivation | |
| CMV | 32 (43.2%) |
| Antiviral treatment | 30 (94%) |
| HSV | 21 (28.4%) |
| Antiviral treatment | 15 (71%) |
| Cause of death, n (%) | |
| Septic shock | 13 (17.1%) |
| Hemorrhagic shock | 12 (15.8%) |
| Cardiogenic shock | 1 (1.3%) |
| Stroke | 2 (2.6%) |
| Multi-organ failure | 3 (3.9%) |
| Other | 6 (7.9%) |
Data are expressed as median (interquartiles) or number (percentage, %)
Obesity was defined by a BMI superior or equal to 30 g/m2
BMI body mass index, NSAID non-steroidal anti-inflammatory drug, ACE angiotensin converting enzyme, ARB angiotensin II receptor blockers, SAPS II Simplified Acute Physiology score, SOFA Sequential Organ Function, ICU intensive care unit, ECMO extra-corporeal membrane oxygenation, MV mechanical ventilation, CMV cytomegalovirus, HSV herpes simplex virus
a3 patients had missing data for BMI